<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arthritis Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Arthritis Res. Ther</journal-id><journal-title-group><journal-title>Arthritis Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="ppub">1478-6354</issn><issn pub-type="epub">1478-6362</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28623945</article-id><article-id pub-id-type="pmc">5473986</article-id><article-id pub-id-type="publisher-id">1331</article-id><article-id pub-id-type="doi">10.1186/s13075-017-1331-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Mir-155 is overexpressed in systemic sclerosis fibroblasts and is required for NLRP3 inflammasome-mediated collagen synthesis during fibrosis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Artlett</surname><given-names>Carol M.</given-names></name><address><email>Carol.artlett@drexelmed.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sassi-Gaha</surname><given-names>Sihem</given-names></name><address><email>Sihem.sassi-gaha@drexelmed.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hope</surname><given-names>Jennifer L.</given-names></name><address><email>jlh434@drexel.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Feghali-Bostwick</surname><given-names>Carol A.</given-names></name><address><email>feghalib@musc.edu</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Katsikis</surname><given-names>Peter D.</given-names></name><address><email>p.katsikis@erasmus.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2181 3113</institution-id><institution-id institution-id-type="GRID">grid.166341.7</institution-id><institution>Department of Microbiology and Immunology, </institution><institution>Drexel University College of Medicine, </institution></institution-wrap>2900 Queen Lane, Philadelphia, PA 19129 USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">000000040459992X</institution-id><institution-id institution-id-type="GRID">grid.5645.2</institution-id><institution>Department of Immunology, </institution><institution>Erasmus University Medical Center, </institution></institution-wrap>Rotterdam, The Netherlands </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2189 3475</institution-id><institution-id institution-id-type="GRID">grid.259828.c</institution-id><institution>Division of Rheumatology &#x00026; Immunology, </institution><institution>Medical University of South Carolina, </institution></institution-wrap>Charleston, SC USA </aff></contrib-group><pub-date pub-type="epub"><day>17</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>17</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="ppub"><year>2017</year></pub-date><volume>19</volume><elocation-id>144</elocation-id><history><date date-type="received"><day>7</day><month>10</month><year>2016</year></date><date date-type="accepted"><day>15</day><month>5</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Despite the important role that microRNAs (miRNAs) play in immunity and inflammation, their involvement in systemic sclerosis (SSc) remains poorly characterized. miRNA-155 (miR-155) plays a role in pulmonary fibrosis and its expression can be induced with interleukin (IL)-1&#x003b2;. SSc fibroblasts have activated inflammasomes that are integrally involved in mediating the myofibroblast phenotype. In light of this, we investigated whether miR-155 played a role in SSc and if its expression was dependent on inflammasome activation.</p></sec><sec><title>Methods</title><p>miR-155 expression was confirmed in SSc dermal and lung fibroblasts by quantitative polymerase chain reaction (PCR). Wild-type and NLRP3-deficient murine fibroblasts were utilized to explore the regulation of miR-155 during inflammasome activation. miR-155-deficient fibroblasts and retroviral transductions with a miR-155 expression or control vectors were used to understand the contribution of miR-155 in fibrosis.</p></sec><sec><title>Results</title><p>miR-155 was significantly increased and the highest expressing miRNA in SSc lung fibroblasts. Its expression was dependent on inflammasome activation as miR-155 expression could be blocked when inflammasome signaling was inhibited. In the absence of miR-155, inflammasome-mediated collagen synthesis could not be induced but was restored when miR-155 was expressed in miR-155-deficient fibroblasts.</p></sec><sec><title>Conclusions</title><p>miR-155 is upregulated in SSc. These results suggest that the inflammasome promotes the expression of miR-155 and that miR-155 is a critical miRNA that drives fibrosis.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Fibrosis</kwd><kwd>NLRP3 inflammasome</kwd><kwd>miR-155</kwd><kwd>Systemic sclerosis</kwd><kwd>IL-1</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001844</institution-id><institution>Scleroderma Foundation</institution></institution-wrap></funding-source></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AR061271</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Systemic sclerosis (SSc) is a chronic autoimmune disease. It is characterized by uncontrolled fibrosis that is directly related to the morbidity and mortality of the disease [<xref ref-type="bibr" rid="CR1">1</xref>]. Fibrotic lesions in SSc have persistently activated myofibroblasts and these cells mediate the excessive deposition of collagen in the dermis and visceral organs and display vascular abnormalities [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]. Patients typically present with an autoantibody profile that often defines disease progression and organ involvement [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. We recently found that activation of the inflammasome orchestrates the increased collagen synthesis in SSc fibroblasts [<xref ref-type="bibr" rid="CR7">7</xref>]. We also found that inhibition of inflammasome signaling significantly abrogated the myofibroblast phenotype [<xref ref-type="bibr" rid="CR7">7</xref>]. Based on these findings, we concluded that inflammasome activation plays a significant role in the pathogenesis of SSc fibrosis.</p><p>MicroRNAs (miRNAs) have been shown to regulate gene expression and specific miRNAs have been reported to be involved in SSc fibrosis [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>]; however, little is known about the regulation of specific miRNAs during fibrosis. miRNA-155 (miR-155) has been identified as having immune regulatory functions and plays a critical role in innate and adaptive immune responses [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>]. Increased miR-155 has been associated with liver [<xref ref-type="bibr" rid="CR15">15</xref>] and lung fibrosis [<xref ref-type="bibr" rid="CR16">16</xref>] and an additional study has shown that the downregulation of miR-155 at wound sites abrogates fibrosis [<xref ref-type="bibr" rid="CR17">17</xref>]. miR-155 can be induced by interleukin (IL)-1&#x003b2; [<xref ref-type="bibr" rid="CR18">18</xref>] and transforming growth factor (TGF)-&#x003b2;1 [<xref ref-type="bibr" rid="CR19">19</xref>]. In light of the observation that IL-1&#x003b2; induces miR-155 and because we found that IL-1&#x003b2; processing by the inflammasome is elevated in SSc fibroblasts [<xref ref-type="bibr" rid="CR7">7</xref>], we investigated whether miR-155 was overexpressed in SSc cells and whether its expression requires activation of the inflammasome. In some of these studies, bleomycin was used to activate the inflammasome and induce IL-1 processing and secretion and we used this molecule to further explore the contribution of the inflammasome activation to miR-155 expression in fibrosis. The results of these studies demonstrate that SSc fibroblasts have increased synthesis of miR-155, and that miR-155 expression is dependent on inflammasome activation. Importantly, miR-155 is required for collagen production following inflammasome activation as cells devoid of miR-155 cannot produce collagen in a fibrotic setting. This suggests that miRNAs are involved in the pathogenesis of SSc and, in particular, miR-155 may be an essential regulator of SSc fibrosis downstream of inflammasome activation.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Human subjects</title><p>Primary fibroblast strains were derived from SSc lung (<italic>n</italic>&#x02009;=&#x02009;9) and normal lung (<italic>n</italic>&#x02009;=&#x02009;5) explants. The lung fibroblasts lines were derived from Caucasian SSc patients aged 46&#x02013;52 years (eight female, one male) with nonspecific interstitial pneumonia, that is usual interstitial pneumonia with or without pulmonary arterial hypertension. Control lung fibroblast lines were established from Caucasian normal individuals (three female, two male) aged 25&#x02013;76 years who had all died due to head trauma. SSc skin-derived fibroblasts (<italic>n</italic>&#x02009;=&#x02009;5) were established from Caucasian SSc patients with diffuse disease aged 40&#x02013;50 years (four female, one male), with Scl-70 or RNA polymerase autoantibodies. Normal dermal fibroblasts (<italic>n</italic>&#x02009;=&#x02009;6) were obtained from Coriell Repositories, Camden, NJ, USA (<italic>n</italic>&#x02009;=&#x02009;4) or obtained from Pittsburgh (<italic>n</italic>&#x02009;=&#x02009;2) and were derived from Caucasian and one Black individual aged 16&#x02013;80 years of age. All of the SSc patients fulfilled the preliminary criteria for the classification of SSc [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. All human-derived fibroblasts were tested between passages 3 and 6.</p></sec><sec id="Sec4"><title>Cell culture</title><p>Normal human primary dermal fibroblasts (<italic>n</italic>&#x02009;=&#x02009;4) and SSc primary dermal fibroblasts (<italic>n</italic>&#x02009;=&#x02009;5) or normal human primary lung fibroblasts (<italic>n</italic>&#x02009;=&#x02009;3) and SSc primary lung fibroblasts (<italic>n</italic>&#x02009;=&#x02009;3) (750,000 cells/dish) were cultured in Dulbecco&#x02019;s modified Eagle&#x02019;s medium (DMEM; Mediatech Inc., Manassas, VA, USA) supplemented with 10% fetal bovine serum (FBS; Mediatech) and 1% penicillin/streptomycin (Mediatech). In the additional experiments, SSc fibroblasts were exposed to 20 &#x003bc;M caspase-1 inhibitor (Z-YVAD(OMe)-FMK (YVAD); Enzo Life Sciences, Plymouth Meeting, PA, USA) for 48 h. RNA was isolated using the Qiagen miRNeasy kit and the culture media was reserved for hydroxyproline assays according to Artlett et al. [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p>Fibroblasts cell lines from murine skin explants were established from NLRP3-deficient mice, miR-155-deficient mice, and wild-type C57BL/6 mice as previously described [<xref ref-type="bibr" rid="CR7">7</xref>]. All fibroblasts derived from the knockout mice were on a C57BL/6 background. miR-155-deficient mice were a kind gift from Dr. Martin Turner (Babraham Institute, UK).</p></sec><sec id="Sec5"><title>miR-155 expression</title><p>miR-155 expression was measured by quantitative real-time polymerase chain reaction (RT-PCR) normalized to SNORD44 for human fibroblasts or SNORD47 for mouse fibroblasts using primers purchased from Quanta Biosciences, Gaithersburg, MD, USA. Total miRNA was reverse transcribed with qScript miRNA cDNA reaction kit (Quanta Biosciences) and quantified with PerfectCT SYBR Green Supermix (Quanta Biosciences) according to the manufacturer&#x02019;s instructions.</p></sec><sec id="Sec6"><title>Fibroblast transduction</title><p>Retroviruses were produced in the Platinum-E cell line (Cell Biolabs). The miR-155-expressing MigR1-miR-155-gfp retrovirus was provided by E. Vigorito (Babraham Institute, UK). A MigR1-control-gfp retrovirus that expressed scrambled miR-155 sequence was used as the control. miR-155-deficient cells were transduced as previously described [<xref ref-type="bibr" rid="CR14">14</xref>] but modified for fibroblasts. Briefly, fibroblasts at 50% confluency were treated with 8 &#x003bc;g/ml polybrene and retrovirus, centrifuged at 2000 g for 90 min, incubated at 37&#x000b0;C for 4 h, and then fresh media was added. Some of the dishes received 10 &#x003bc;M bleomycin or 50 ng/ml IL-1 receptor antagonist (IL-1RA) at 0 and 24 h post-transduction, and were then recovered for hydroxyproline analyses. Transduction efficiency of both retroviral constructs was determined by green fluorescent protein (GFP) expression to be approximately 10% using flow cytometry.</p></sec><sec id="Sec7"><title>Western blotting</title><p>Fibroblasts (C57BL/6 and miR-155KO) were cultured as described with or without 10 &#x003bc;M bleomycin; 200 &#x003bc;g of whole cell lysate was size fractionated on an 8% SDS polyacrylamide gel and the proteins transferred to a PVDF membrane (ThermoFisher Scientific, Waltham, MA, USA). Nonspecific binding sites were blocked with 5% skim milk and then probed with rabbit-anti-mouse TGF-&#x003b2;1 or &#x003b2;-actin (Santa Cruz Biotechnologies, Santa Cruz, CA, USA) overnight at 4&#x000b0;C. The membrane was washed and incubated with goat-anti-rabbit-HRP (Jackson Immunoresearch, West Grove, PA, USA). The horseradish peroxidase (HRP) signal was developed with SuperSignal Chemiluminescent Substrate (ThermoFisher Scientific). Band densities were quantified using ImageQuant LAS4000. TGF-&#x003b2;1 bands were normalized to the &#x003b2;-actin levels.</p></sec><sec id="Sec8"><title>Statistical analyses</title><p>The Mann Whitney <italic>t</italic> test or Wilcoxon matched-pairs signed-rank test were used to analyze the data by GraphPad Prism 7. A <italic>p</italic> value &#x0003c;0.05 was considered significant.</p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>miRNA-155 is overexpressed in SSc dermal and lung fibroblasts</title><p>miR-155 has been reported to be elevated in fibrosis and we wanted to determine whether this was a relevant miRNA for SSc. We found the relative expression of miR-155 in SSc lung fibroblasts (<italic>n</italic>&#x02009;=&#x02009;9) to be 3.65-times more than that of normal lung fibroblasts (<italic>n</italic>&#x02009;=&#x02009;5) (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01; Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>). We also found that SSc dermal fibroblasts (<italic>n</italic>&#x02009;=&#x02009;5) had twice the relative expression of miR-155 than normal dermal fibroblasts (<italic>n</italic>&#x02009;=&#x02009;6) (<italic>p</italic>&#x02009;=&#x02009;0.04; Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>). These findings suggest that the increased miR-155 expression in fibroblasts may be contributing to fibrosis.<fig id="Fig1"><label>Fig. 1</label><caption><p>miR-155 has increased expression in systemic sclerosis (<italic>SSc</italic>) lung and dermal fibroblasts. <bold>a</bold> Lung fibroblasts (<italic>n</italic>&#x02009;=&#x02009;9 SSc; <italic>n</italic>&#x02009;=&#x02009;5 control) and <bold>b</bold> dermal fibroblasts (<italic>n</italic>&#x02009;=&#x02009;5 SSc; <italic>n</italic>&#x02009;=&#x02009;6 control) were assayed for miR-155 levels as described in the methods. miR-155 levels were normalized to SNORD44. Statistical analyses was by Mann-Whitney <italic>t</italic> test</p></caption><graphic xlink:href="13075_2017_1331_Fig1_HTML" id="MO1"/></fig>
</p></sec><sec id="Sec11"><title>miRNA-155 is induced by inflammasome activation</title><p>We have previously shown that SSc fibroblasts have an activated inflammasome [<xref ref-type="bibr" rid="CR7">7</xref>] and it has been reported that miR-155 expression can be induced by IL-1&#x003b2; [<xref ref-type="bibr" rid="CR18">18</xref>]. We therefore wanted to determine whether inflammasome activation could be inducing miR-155. SSc fibroblasts (<italic>n</italic>&#x02009;=&#x02009;7) were cultured with the inflammasome inhibitor YVAD for 48 h. We found that in the presence of the caspase-1 inhibitor miR-155 was significantly reduced (<italic>p</italic>&#x02009;=&#x02009;0.03; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref>). Further confirming our previous findings, total collagen synthesis was also significantly reduced when caspase-1 was inhibited with YVAD (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2b</xref>). These data suggest that miR-155 expression is dependent on caspase-1 activation and that miR-155 upregulation could correlate with collagen production in SSc.<fig id="Fig2"><label>Fig. 2</label><caption><p>miR-155 expression requires the NLRP3 inflammasome. <bold>a</bold> Systemic sclerosis (<italic>SSc</italic>) lung fibroblasts (<italic>n</italic>&#x02009;=&#x02009;7) were treated with 20 &#x003bc;M YVAD for 48 h. miRNA was extracted and the resulting cDNA was assayed for miR-155 levels normalized to SNORD44. <bold>b</bold> Hydroxyproline was measured in the culture supernatants from <bold>a</bold>. Statistical analyses for <bold>a</bold> and <bold>b</bold> used the Wilcoxon ranked paired <italic>t</italic> test. <bold>c</bold> In mouse cells, miR-155 expression was induced with 20 &#x003bc;M bleomycin (<italic>Bleo</italic>)&#x02009;+&#x02009;20 &#x003bc;M YVAD for 48 h and analyzed for miR-155 expression normalized to SNORD47. Data are presented as the average from two independent experiments with three replicates (<italic>n</italic>&#x02009;=&#x02009;6 for each condition)&#x02009;+&#x02009;SEM. <bold>d</bold> Hydroxyproline was measured from the culture supernatants from <bold>c</bold>. Statistical analyses for <bold>c</bold> and <bold>d</bold> used the Mann-Whitney <italic>t</italic> test</p></caption><graphic xlink:href="13075_2017_1331_Fig2_HTML" id="MO2"/></fig>
</p><p>In addition, because we found the NLRP3 inflammasome to be integral in SSc fibrosis [<xref ref-type="bibr" rid="CR7">7</xref>], we explored whether NLRP3-deficient fibroblasts (NLRP3KO) could express miR-155. B6 and NLRP3KO fibroblasts were cultured with bleomycin&#x02009;&#x000b1;&#x02009;YVAD, and miR-155 expression was measured. In the wild-type B6 fibroblasts, the relative expression of miR-155 was induced with bleomycin (<italic>p</italic>&#x02009;=&#x02009;0.01; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2c</xref>) and the induced expression of miR-155 could be abolished with YVAD (<italic>p</italic>&#x02009;=&#x02009;0.02; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2c</xref>). Furthermore, miR-155 was not expressed in NLRP3KO fibroblasts (<italic>p</italic>&#x02009;=&#x02009;0.01; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2c</xref>) and could not be induced at all with bleomycin (<italic>p</italic>&#x02009;=&#x02009;0.01; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2c</xref>). Correspondingly, we then examined hydroxyproline levels and found that bleomycin induced collagen (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2d</xref>) and YVAD blocked this process (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2d</xref>). These data suggest that the NLRP3 inflammasome and caspase-1 may play a role in miR-155 expression in fibroblasts.</p></sec><sec id="Sec12"><title>miRNA-155 is required for inflammasome-driven collagen synthesis</title><p>Having established that both miR-155 expression and collagen production by fibroblasts were upregulated by inflammasome activation, it was important to determine whether miR-155 expression was required for collagen production during fibrosis. To address this, we first tested whether miR-155KO fibroblasts responded to bleomycin. We found that, unlike the B6 fibroblasts responding to bleomycin (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01; Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>), bleomycin did not induce collagen synthesis in the miR-155KO fibroblasts (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001; Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>Collagen synthesis mediated by the inflammasome requires miR-155. <bold>a</bold> Hydroxyproline levels were measured in the culture media from B6 fibroblasts and miR-155-deficient fibroblasts (miR-155KO)&#x02009;+&#x02009;10 &#x003bc;M bleomycin (<italic>Bleo</italic>) after 48 h. <bold>b</bold> Culture media hydroxyproline levels from miR-155KO fibroblasts transduced with the control (<italic>Ctl</italic>) vector or the miR-155 expressing vector&#x02009;+&#x02009;10 &#x003bc;M Bleo after 48 h. Data for both <bold>a</bold> and <bold>b</bold> are presented as the average from two independent experiments with three replicates (<italic>n</italic>&#x02009;=&#x02009;6 for each condition)&#x02009;+&#x02009;SEM using the Mann-Whitney <italic>t</italic> test. <italic>ns</italic> Not significant</p></caption><graphic xlink:href="13075_2017_1331_Fig3_HTML" id="MO3"/></fig>
</p><p>To directly confirm this observation and to prove that miR-155 facilitates fibrosis, we transduced miR-155KO fibroblasts with a miR-155 retroviral expression vector or the retroviral control vector and then stimulated the fibroblasts with bleomycin. When cells were transduced with the control vector, collagen synthesis could not be induced with bleomycin (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref>). However, after restoration of miR-155 in the miR-155KO fibroblasts, there was a significant induction of total collagen, even without bleomycin stimulation (<italic>p</italic>&#x02009;=&#x02009;0.03; Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref>) and this effect was further enhanced with bleomycin (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001; Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref>). These data indicate that miR-155 is required for fibrosis.</p></sec><sec id="Sec13"><title>miRNA-155 modulates fibrosis via IL-1 signaling</title><p>We found increased hydroxyproline when miR-155 was overexpressed in fibroblasts; however, only 10% of the fibroblasts were transduced by the miR-155 retrovirus (data not shown). This suggested that there might be an indirect mechanism driving the miR-155-mediated fibrotic response. IL-1 has been reported to promote miR-155 expression, and so we questioned whether miR-155 could promote IL-1 transcription that synergizes with the activation of the inflammasome; we therefore blocked the IL-1 receptor with its antagonist (IL-1RA). In repeat experiments, in the absence of miR-155, IL-1RA had no effect on hydroxyproline levels (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4a</xref>); however, in the presence of miR-155, IL-1RA completely abrogated bleomycin-induced hydroxyproline (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01; Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4a</xref>). In addition, the spike in the level of hydroxyproline that was observed when miR-155KO fibroblasts were transduced with the miR-155 vector (without bleomycin stimulation) was also via a mechanism that entailed IL-1, as this spike was abolished with IL-1RA (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01; Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4a</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><p>miR-155 regulates fibrosis via interleukin-1 (<italic>IL-1</italic>) and IL-1 induces miR-155. <bold>a</bold> miR-155KO fibroblasts were transduced with the miR-155 expression vector or the control (<italic>Ctl</italic>) vector. Some of the dishes received 10 &#x003bc;M bleomycin (<italic>Bleo</italic>) at 0 h and some of the cells also received 50 ng/ml IL-1 receptor antagonist (<italic>IL-1RA</italic>) at 0 and 24 h. Media was recovered after 48 h and hydroxyproline was measured (<italic>n</italic>&#x02009;=&#x02009;9 replicates). <bold>b</bold> Dose-dependent induction of miR-155 in fibroblasts (<italic>n</italic>&#x02009;=&#x02009;7 replicates). <bold>c</bold> Graphical representation of transforming growth factor beta (<italic>TGF-&#x003b2;</italic>) levels in miR-155KO and B6 cells&#x02009;&#x000b1;&#x02009;bleo. <bold>d</bold> Representative Western blot (one of three samples independently tested). Data are presented as averages&#x02009;+&#x02009;SEM using the Mann-Whitney <italic>t</italic> test. <italic>ns</italic> Not significant</p></caption><graphic xlink:href="13075_2017_1331_Fig4_HTML" id="MO4"/></fig>
</p><p>Confirming the data by Pottier et al. [<xref ref-type="bibr" rid="CR18">18</xref>], we found that the addition of IL-1 to fibroblasts induced miR-155 in a dose-dependent manner (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4b</xref>). However, we found this expression was not transient in fibroblasts and that miR-155 expression was still elevated at 48 h at the time point when total miRNA was isolated for the other experiments. Taken together, these data suggest that in fibroblasts activation of the inflammasome is involved in IL-1-mediated expression of miR-155 and that miR-155 synergizes with the inflammasome to drive collagen synthesis during fibrosis. Furthermore, these data also imply that miR-155 provides a feed-forward mechanism promoting IL-1 transcription that can lead to upregulated collagen synthesis via IL-1 receptor signaling and further miR-155 expression.</p><p>We also found that miR-155 was necessary for increased TGF-&#x003b2;1 protein levels. We stimulated C57BL/6 and the miR-155KO fibroblasts with bleomycin and measured TGF-&#x003b2; 1 protein levels in fibroblasts. We found that there was a significant induction of TGF-&#x003b2;1 in the B6 fibroblasts; however in the miR-155KO TGF-&#x003b2;1 could not be induced. This suggests that miR-155 is driving TGF-&#x003b2;1 expression and contributing to the fibrotic pathology in these cells.</p></sec></sec><sec id="Sec14"><title>Discussion</title><p>miR-155 has been studied previously in other fibrotic conditions; however, little is known about its regulation in SSc fibrosis. Pottier et al. [<xref ref-type="bibr" rid="CR18">18</xref>] reported that miR-155-overexpressing fibroblasts had increased motility on collagen gels suggesting that this miRNA could help to mediate wound closure, whereas the knockdown of miR-155 during wound healing abrogated fibrosis. A recently published study reports on the role of miR-155 in SSc fibrosis [<xref ref-type="bibr" rid="CR22">22</xref>]; however, this study did not explore what caused the increase in miR-155 in SSc fibroblasts but investigated the downstream responses mediated by miR-155. Yan et al. [<xref ref-type="bibr" rid="CR22">22</xref>] found that miR-155 regulated the Akt and Wnt/&#x003b2;-catenin pathways. Our study further confirms and helps to define the crucial role of miR-155 in SSc fibrosis.</p><p>miR-155 expression is upregulated by IL-1 and we explored this observation in light of our recent finding that IL-1 and the inflammasome plays a significant role in SSc fibrosis [<xref ref-type="bibr" rid="CR7">7</xref>]. We found that miR-155 expression in SSc fibroblasts is driven by inflammasome activation since inhibition of the inflammasome signaling cascade with a caspase antagonist abolished miR-155 expression and, in turn, significantly lowered collagen (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Our previous study used bleomycin to activate the inflammasome and upregulate collagen via IL-1 expression [<xref ref-type="bibr" rid="CR7">7</xref>]; therefore, in these studies, we used bleomycin to activate the inflammasome and to determine the role of the NLRP3 inflammasome in miR-155 expression. Thus, to further confirm the role of the inflammasome in miR-155 expression, we show for the first time that NLRP3KO fibroblasts cannot induce miR-155 expression when stimulated with bleomycin (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2c</xref>). Taken together, this suggests that the NLRP3 inflammasome is required for miR-155 expression. We next asked whether miR-155 participates in fibrosis and found that bleomycin cannot induce collagen synthesis in the miR-155KO fibroblasts (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>), whereas the restoration of miR-155 using a viral vector resulted in increased collagen (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref>). IL-1 was found to induce miR-155 expression (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4b</xref>) and the synthesis of collagen in miR-155-sufficient fibroblasts, and that this was mediated via IL-1 since IL-1RA abolished these findings (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4a</xref>).</p><p>Previous research by Kong et al. [<xref ref-type="bibr" rid="CR19">19</xref>] found that TGF-&#x003b2;1 upregulated the expression of miR-155, leading to altered SMAD signaling; however, another study found miR-155 to be decreased by TGF-&#x003b2; [<xref ref-type="bibr" rid="CR18">18</xref>]. While the data from these findings are confounding, they suggest that the expression of miR-155 by TGF-&#x003b2; could be dependent on the pathological setting, e.g., fibrosis vs. wound healing, and the cells they are directly acting in. We found that, in the absence of miR-155, TGF-&#x003b2; was not induced, supporting the findings by Zhang et al. that miR-155 can induce TGF-&#x003b2; expression [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p>The data presented here imply that blockade of the IL-1 receptor or sequestration of IL-1 from the circulation could be of therapeutic benefit to SSc patients. Drugs such as kineret, rilonacept, or ilaris may prove efficacious for this, as yet, untreatable pathology. Currently, there is a placebo-controlled clinical trial underway to determine whether rilonacept could be used to treat SSc. Rilonacept sequesters IL-1 from the circulation using an antibody that binds and inactivates IL-1. Administration of IL-1RA, which blocks IL-1 from binding its receptor, has been used in various human and animal studies to prevent various organ fibroses [<xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref>] and it is further suggested that blockade of IL-1 signaling may also be beneficial. Furthermore, elevated IL-1 or decreased IL-1RA has been directly associated with fibrosis. Decreased expression of IL-1RA has been found in idiopathic pulmonary fibrosis and this has been specifically linked to the single nucleotide polymorphism at rs2637988 which controls expression of the gene [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Children deficient in IL-1RA have chronic inflammation that can lead to fibrosis of the lungs or vertebra, if they survive long enough [<xref ref-type="bibr" rid="CR32">32</xref>]. Further supporting this observation, the uncontrolled expression of IL-1 in Familial Mediterranean Fever or Muckle-Wells Syndrome has been associated with an increased risk for peritoneal fibrosis [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>].</p></sec><sec id="Sec15"><title>Conclusions</title><p>These data imply that miR-155 is a critical regulator in the fibrotic process and that miR-155 expression requires the NLRP3 inflammasome processing of IL-1 leading to fibrosis. Thus, we propose that the inflammasome is the initiator causing IL-1 transcription and autocrine signaling that drives the expression of miR-155 via an IL-1 signaling mechanism (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). miR-155 synergizes with the inflammasome to induce a positive feed-forward signal that further promotes IL-1 release and autocrine signaling leading to continual collagen expression. Inhibiting either the IL-1 receptor with its antagonist or the inflammasome with YVAD breaks this cycle, and abrogates miR-155 expression and fibrosis.<fig id="Fig5"><label>Fig. 5</label><caption><p>miR-155 and interleukin-1 (<italic>IL-1</italic>) provide a feed-forward mechanism during fibrosis. In fibroblasts, activation of the inflammasome drives miR-155 expression via IL-1 autocrine signaling that further enhances IL-1 transcription and leads to fibrosis. Blockade of the IL-1 receptor or the inflammasome abrogates this process</p></caption><graphic xlink:href="13075_2017_1331_Fig5_HTML" id="MO5"/></fig>
</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>B6</term><def><p>C57BL6</p></def></def-item><def-item><term>IL</term><def><p>Interleukin</p></def></def-item><def-item><term>IL-1RA</term><def><p>interleukin-1 receptor antagonist</p></def></def-item><def-item><term>miR-155</term><def><p>MicroRNA-155</p></def></def-item><def-item><term>miRNA</term><def><p>MicroRNA</p></def></def-item><def-item><term>NLRP3</term><def><p>NOD-like receptor family, pyrin domain containing 3</p></def></def-item><def-item><term>NLRP3KO</term><def><p>NLRP3-deficient</p></def></def-item><def-item><term>SSc</term><def><p>Systemic sclerosis</p></def></def-item><def-item><term>TGF</term><def><p>Transforming growth factor</p></def></def-item><def-item><term>YVAD</term><def><p>Z-YVAD(OMe)-FMK</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>This work was funded by a research award from the Scleroderma Foundation to CMA and by NIH AR061271 to CAF-B.</p><sec id="FPar1"><title>Availability of data and materials</title><p>Not applicable.</p></sec><sec id="FPar2"><title>Authors&#x02019; contributions</title><p>CMA conceived and designed the experiments, analyzed the data, and wrote the manuscript; SS-G performed the experiments and revised the manuscript; CAF-B established explants from SSc and normal fibroblasts and revised the manuscript; JLH generated retroviral vectors and performed flow cytometry and revised the manuscript; PDK conceived and designed the experiments and wrote the manuscript. All authors listed have read the manuscript for content and have approved the final version.</p></sec><sec id="FPar3"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar4"><title>Consent for publication</title><p>No specific information has been given about any individual in this manuscript.</p></sec><sec id="FPar5"><title>Ethics approval</title><p>Human studies, with exempt status, were approved by the Institutional Review Board at Drexel University due to samples being de-identified to CMA, whereas full Institutional Review Board approval for sample collection was given by the University of Pittsburgh and informed consent was obtained at Pittsburgh University under the protocol to CAF-B.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varga</surname><given-names>J</given-names></name></person-group><article-title>Systemic sclerosis: an update</article-title><source>Bull NYU Hosp Jt Dis</source><year>2008</year><volume>66</volume><fpage>198</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">18937632</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirk</surname><given-names>TZ</given-names></name><name><surname>Mark</surname><given-names>ME</given-names></name><name><surname>Chua</surname><given-names>CC</given-names></name><name><surname>Chua</surname><given-names>BH</given-names></name><name><surname>Mayes</surname><given-names>MD</given-names></name></person-group><article-title>Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1</article-title><source>J Biol Chem</source><year>1995</year><volume>270</volume><fpage>3423</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1074/jbc.270.41.24270</pub-id><pub-id pub-id-type="pmid">7852429</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abraham</surname><given-names>DJ</given-names></name><name><surname>Eckes</surname><given-names>B</given-names></name><name><surname>Rajkumar</surname><given-names>V</given-names></name><name><surname>Krieg</surname><given-names>T</given-names></name></person-group><article-title>New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma</article-title><source>Curr Rheum Rep</source><year>2007</year><volume>9</volume><fpage>136</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1007/s11926-007-0008-z</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomasek</surname><given-names>JJ</given-names></name><name><surname>Gabbiani</surname><given-names>G</given-names></name><name><surname>Hinz</surname><given-names>B</given-names></name><name><surname>Chaponnier</surname><given-names>C</given-names></name><name><surname>Brown</surname><given-names>RA</given-names></name></person-group><article-title>Myofibroblasts and mechano-regulation of connective tissue remodelling</article-title><source>Nat Rev</source><year>2002</year><volume>3</volume><fpage>349</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1038/nrm809</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>OC</given-names></name><name><surname>Fertig</surname><given-names>N</given-names></name><name><surname>Lucas</surname><given-names>M</given-names></name><name><surname>Somogyi</surname><given-names>N</given-names></name><name><surname>Medsger</surname><given-names>TA</given-names><suffix>Jr</suffix></name></person-group><article-title>Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis</article-title><source>J Rheumatol</source><year>2007</year><volume>34</volume><fpage>104</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17117486</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parodi</surname><given-names>A</given-names></name><name><surname>Drosera</surname><given-names>M</given-names></name><name><surname>Barbieri</surname><given-names>L</given-names></name><name><surname>Rebora</surname><given-names>A</given-names></name></person-group><article-title>Scleroderma subsets are best detected by the simultaneous analysis of the autoantibody profile using commercial ELISA</article-title><source>Dermatology</source><year>2002</year><volume>204</volume><fpage>29</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1159/000051806</pub-id><pub-id pub-id-type="pmid">11834846</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Artlett</surname><given-names>CM</given-names></name><name><surname>Sassi-Gaha</surname><given-names>S</given-names></name><name><surname>Rieger</surname><given-names>JL</given-names></name><name><surname>Boesteanu</surname><given-names>AC</given-names></name><name><surname>Feghali-Bostwick</surname><given-names>CA</given-names></name><name><surname>Katsikis</surname><given-names>PD</given-names></name></person-group><article-title>The inflammasome activating caspase-1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis</article-title><source>Arthritis Rheum</source><year>2011</year><volume>63</volume><fpage>3563</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1002/art.30568</pub-id><pub-id pub-id-type="pmid">21792841</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawashita</surname><given-names>Y</given-names></name><name><surname>Jinnin</surname><given-names>M</given-names></name><name><surname>Makino</surname><given-names>T</given-names></name><name><surname>Kajihara</surname><given-names>I</given-names></name><name><surname>Makino</surname><given-names>K</given-names></name><name><surname>Honda</surname><given-names>N</given-names></name><name><surname>Masuguchi</surname><given-names>S</given-names></name><name><surname>Fukushima</surname><given-names>S</given-names></name><name><surname>Inoue</surname><given-names>Y</given-names></name><name><surname>Ihn</surname><given-names>H</given-names></name></person-group><article-title>Circulating miR-29a levels in patients with scleroderma spectrum disorder</article-title><source>J Dermatol Sci</source><year>2011</year><volume>61</volume><fpage>67</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.jdermsci.2010.11.007</pub-id><pub-id pub-id-type="pmid">21129921</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maurer</surname><given-names>B</given-names></name><name><surname>Stanczyk</surname><given-names>J</given-names></name><name><surname>Jungel</surname><given-names>A</given-names></name><name><surname>Akhmetshina</surname><given-names>A</given-names></name><name><surname>Trenkmann</surname><given-names>M</given-names></name><name><surname>Brock</surname><given-names>M</given-names></name><name><surname>Kowal-Bielecka</surname><given-names>O</given-names></name><name><surname>Gay</surname><given-names>RE</given-names></name><name><surname>Michel</surname><given-names>BA</given-names></name><name><surname>Distler</surname><given-names>JH</given-names></name><etal/></person-group><article-title>MicroRNA-29, a key regulator of collagen expression in systemic sclerosis</article-title><source>Arthritis Rheum</source><year>2010</year><volume>62</volume><fpage>1733</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1002/art.27443</pub-id><pub-id pub-id-type="pmid">20201077</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>He</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group><article-title>Molecular characterisation of porcine miR-155 and its regulatory roles in the TLR3/TLR4 pathways</article-title><source>Dev Comp Immunol</source><year>2012</year><volume>39</volume><fpage>110</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.dci.2012.01.001</pub-id><pub-id pub-id-type="pmid">22301067</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vigorito</surname><given-names>E</given-names></name><name><surname>Perks</surname><given-names>KL</given-names></name><name><surname>Abreu-Goodger</surname><given-names>C</given-names></name><name><surname>Bunting</surname><given-names>S</given-names></name><name><surname>Xiang</surname><given-names>Z</given-names></name><name><surname>Kohlhaas</surname><given-names>S</given-names></name><name><surname>Das</surname><given-names>PP</given-names></name><name><surname>Miska</surname><given-names>EA</given-names></name><name><surname>Rodriguez</surname><given-names>A</given-names></name><name><surname>Bradley</surname><given-names>A</given-names></name><etal/></person-group><article-title>microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells</article-title><source>Immunity</source><year>2007</year><volume>27</volume><fpage>847</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2007.10.009</pub-id><pub-id pub-id-type="pmid">18055230</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thai</surname><given-names>TH</given-names></name><name><surname>Calado</surname><given-names>DP</given-names></name><name><surname>Casola</surname><given-names>S</given-names></name><name><surname>Ansel</surname><given-names>KM</given-names></name><name><surname>Xiao</surname><given-names>C</given-names></name><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>Murphy</surname><given-names>A</given-names></name><name><surname>Frendewey</surname><given-names>D</given-names></name><name><surname>Valenzuela</surname><given-names>D</given-names></name><name><surname>Kutok</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Regulation of the germinal center response by microRNA-155</article-title><source>Science</source><year>2007</year><volume>316</volume><fpage>604</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1126/science.1141229</pub-id><pub-id pub-id-type="pmid">17463289</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Connell</surname><given-names>RM</given-names></name><name><surname>Kahn</surname><given-names>D</given-names></name><name><surname>Gibson</surname><given-names>WS</given-names></name><name><surname>Round</surname><given-names>JL</given-names></name><name><surname>Scholz</surname><given-names>RL</given-names></name><name><surname>Chaudhuri</surname><given-names>AA</given-names></name><name><surname>Kahn</surname><given-names>ME</given-names></name><name><surname>Rao</surname><given-names>DS</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group><article-title>MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development</article-title><source>Immunity</source><year>2010</year><volume>33</volume><fpage>607</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2010.09.009</pub-id><pub-id pub-id-type="pmid">20888269</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gracias</surname><given-names>DT</given-names></name><name><surname>Stelekati</surname><given-names>E</given-names></name><name><surname>Hope</surname><given-names>JL</given-names></name><name><surname>Boesteanu</surname><given-names>AC</given-names></name><name><surname>Doering</surname><given-names>TA</given-names></name><name><surname>Norton</surname><given-names>J</given-names></name><name><surname>Mueller</surname><given-names>YM</given-names></name><name><surname>Fraietta</surname><given-names>JA</given-names></name><name><surname>Wherry</surname><given-names>EJ</given-names></name><name><surname>Turner</surname><given-names>M</given-names></name><etal/></person-group><article-title>The microRNA miR-155 controls CD8(+) T cell responses by regulating interferon signaling</article-title><source>Nat Immunol</source><year>2013</year><volume>14</volume><fpage>593</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1038/ni.2576</pub-id><pub-id pub-id-type="pmid">23603793</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bala</surname><given-names>S</given-names></name><name><surname>Csak</surname><given-names>T</given-names></name><name><surname>Saha</surname><given-names>B</given-names></name><name><surname>Zatsiorsky</surname><given-names>J</given-names></name><name><surname>Kodys</surname><given-names>K</given-names></name><name><surname>Catalano</surname><given-names>D</given-names></name><name><surname>Szabo</surname><given-names>G</given-names></name></person-group><article-title>The pro-inflammatory effects of miR-155 promote liver fibrosis and alcohol-induced steatohepatitis</article-title><source>J Hepatol</source><year>2016</year><volume>64</volume><fpage>1378</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2016.01.035</pub-id><pub-id pub-id-type="pmid">26867493</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>CC</given-names></name><name><surname>Chen</surname><given-names>WD</given-names></name><name><surname>Shen</surname><given-names>WL</given-names></name><name><surname>Ruan</surname><given-names>CC</given-names></name><name><surname>Zhu</surname><given-names>LM</given-names></name><name><surname>Zhu</surname><given-names>DL</given-names></name><name><surname>Gao</surname><given-names>PJ</given-names></name></person-group><article-title>MicroRNA-155 regulates angiotensin II type 1 receptor expression and phenotypic differentiation in vascular adventitial fibroblasts</article-title><source>Biochem Biophys Res Commun</source><year>2010</year><volume>400</volume><fpage>483</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2010.08.067</pub-id><pub-id pub-id-type="pmid">20735984</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>LL</given-names></name><name><surname>Liu</surname><given-names>JQ</given-names></name><name><surname>Bai</surname><given-names>XZ</given-names></name><name><surname>Fan</surname><given-names>L</given-names></name><name><surname>Han</surname><given-names>F</given-names></name><name><surname>Jia</surname><given-names>WB</given-names></name><name><surname>Su</surname><given-names>LL</given-names></name><name><surname>Shi</surname><given-names>JH</given-names></name><name><surname>Tang</surname><given-names>CW</given-names></name><name><surname>Hu</surname><given-names>DH</given-names></name></person-group><article-title>Acute downregulation of miR-155 at wound sites leads to a reduced fibrosis through attenuating inflammatory response</article-title><source>Biochem Biophys Res Commun</source><year>2014</year><volume>453</volume><fpage>153</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2014.09.077</pub-id><pub-id pub-id-type="pmid">25264197</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pottier</surname><given-names>N</given-names></name><name><surname>Maurin</surname><given-names>T</given-names></name><name><surname>Chevalier</surname><given-names>B</given-names></name><name><surname>Puissegur</surname><given-names>MP</given-names></name><name><surname>Lebrigand</surname><given-names>K</given-names></name><name><surname>Robbe-Sermesant</surname><given-names>K</given-names></name><name><surname>Bertero</surname><given-names>T</given-names></name><name><surname>Lino Cardenas</surname><given-names>CL</given-names></name><name><surname>Courcot</surname><given-names>E</given-names></name><name><surname>Rios</surname><given-names>G</given-names></name><etal/></person-group><article-title>Identification of keratinocyte growth factor as a target of microRNA-155 in lung fibroblasts: implication in epithelial-mesenchymal interactions</article-title><source>PLoSOne</source><year>2009</year><volume>4</volume><fpage>e6718</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0006718</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>JJ</given-names></name><name><surname>Coppola</surname><given-names>D</given-names></name><name><surname>Dalton</surname><given-names>WS</given-names></name><name><surname>Cheng</surname><given-names>JQ</given-names></name></person-group><article-title>MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA</article-title><source>Mol Cell Biol</source><year>2008</year><volume>28</volume><fpage>6773</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1128/MCB.00941-08</pub-id><pub-id pub-id-type="pmid">18794355</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masi</surname><given-names>AT</given-names></name><name><surname>Rodnan</surname><given-names>GP</given-names></name><name><surname>Medsger</surname><given-names>TA</given-names></name><name><surname>Altman</surname><given-names>RD</given-names></name><name><surname>D&#x02019;Angelo</surname><given-names>WA</given-names></name><name><surname>Fries</surname><given-names>JF</given-names></name><name><surname>LeRoy</surname><given-names>EC</given-names></name><name><surname>Kirsner</surname><given-names>AB</given-names></name><name><surname>Mackenzie</surname><given-names>AH</given-names></name><name><surname>McShane</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Preliminary criteria for the classification of systemic sclerosis (scleroderma) Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee</article-title><source>Arthritis Rheum</source><year>1980</year><volume>23</volume><fpage>581</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1002/art.1780230510</pub-id><pub-id pub-id-type="pmid">7378088</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LeRoy</surname><given-names>EC</given-names></name><name><surname>Black</surname><given-names>CM</given-names></name><name><surname>Fleischmajer</surname><given-names>R</given-names></name><name><surname>Jablonska</surname><given-names>S</given-names></name><name><surname>Krieg</surname><given-names>T</given-names></name><name><surname>Medsger</surname><given-names>TA</given-names></name><name><surname>Rowell</surname><given-names>N</given-names></name><name><surname>Wollheim</surname><given-names>F</given-names></name></person-group><article-title>Scleroderma (systemic sclerosis): classification, subsets and pathogenesis</article-title><source>J Rheumatol</source><year>1988</year><volume>15</volume><fpage>202</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">3361530</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Bao</surname><given-names>C</given-names></name><name><surname>Fu</surname><given-names>Q</given-names></name></person-group><article-title>Targeting miR-155 to treat experimental scleroderma</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><fpage>20314</fpage><pub-id pub-id-type="doi">10.1038/srep20314</pub-id><pub-id pub-id-type="pmid">26828700</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name></person-group><article-title>miR-155 regulates high glucose-induced cardiac fibrosis via the TGF-beta signaling pathway</article-title><source>Molec BioSystems</source><year>2016</year><volume>13</volume><fpage>215</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1039/C6MB00649C</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>CA</given-names></name><name><surname>Toth</surname><given-names>AP</given-names></name><name><surname>Magnussen</surname><given-names>B</given-names></name></person-group><article-title>Clinical benefits of intra-articular anakinra for arthrofibrosis</article-title><source>Orthopedics</source><year>2010</year><volume>33</volume><fpage>877</fpage><pub-id pub-id-type="pmid">21162510</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magnussen</surname><given-names>RA</given-names></name><name><surname>Brown</surname><given-names>CA</given-names></name><name><surname>Lawrence</surname><given-names>TJ</given-names></name><name><surname>Toth</surname><given-names>AP</given-names></name></person-group><article-title>Intra-articular anakinra for the treatment of persistent inflammation and arthrofibrosis following anterior cruciate ligament reconstruction</article-title><source>Duke Orthopedic J</source><year>2011</year><volume>1</volume><fpage>51</fpage><lpage>6</lpage></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>HY</given-names></name><name><surname>Nikolic-Paterson</surname><given-names>DJ</given-names></name><name><surname>Mu</surname><given-names>W</given-names></name><name><surname>Vannice</surname><given-names>JL</given-names></name><name><surname>Atkins</surname><given-names>RC</given-names></name></person-group><article-title>Interleukin-1 receptor antagonist halts the progression of established crescentic glomerulonephritis in the rat</article-title><source>Kidney Int</source><year>1995</year><volume>47</volume><fpage>1303</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/ki.1995.185</pub-id><pub-id pub-id-type="pmid">7637259</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gasse</surname><given-names>P</given-names></name><name><surname>Mary</surname><given-names>C</given-names></name><name><surname>Guenon</surname><given-names>I</given-names></name><name><surname>Noulin</surname><given-names>N</given-names></name><name><surname>Charron</surname><given-names>S</given-names></name><name><surname>Schnyder-Candrian</surname><given-names>S</given-names></name><name><surname>Schnyder</surname><given-names>B</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name><name><surname>Quesniaux</surname><given-names>VFJ</given-names></name><name><surname>Lagente</surname><given-names>V</given-names></name><etal/></person-group><article-title>IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice</article-title><source>J Clin Invest</source><year>2007</year><volume>117</volume><fpage>3786</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">17992263</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aouba</surname><given-names>A</given-names></name><name><surname>Georgin-Lavialle</surname><given-names>S</given-names></name><name><surname>Pagnoux</surname><given-names>C</given-names></name><name><surname>Martin Silva</surname><given-names>N</given-names></name><name><surname>Renand</surname><given-names>A</given-names></name><name><surname>Galateau-Salle</surname><given-names>F</given-names></name><name><surname>Le Toquin</surname><given-names>S</given-names></name><name><surname>Bensadoun</surname><given-names>H</given-names></name><name><surname>Larousserie</surname><given-names>F</given-names></name><name><surname>Silvera</surname><given-names>S</given-names></name><etal/></person-group><article-title>Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease</article-title><source>Blood</source><year>2010</year><volume>116</volume><fpage>4070</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-04-279240</pub-id><pub-id pub-id-type="pmid">20724540</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adam</surname><given-names>Z</given-names></name><name><surname>Szturz</surname><given-names>P</given-names></name><name><surname>Buckova</surname><given-names>P</given-names></name><name><surname>Cervinkova</surname><given-names>I</given-names></name><name><surname>Koukalova</surname><given-names>R</given-names></name><name><surname>Rehak</surname><given-names>Z</given-names></name><name><surname>Krejci</surname><given-names>M</given-names></name><name><surname>Pour</surname><given-names>L</given-names></name><name><surname>Zahradova</surname><given-names>L</given-names></name><name><surname>Hajek</surname><given-names>R</given-names></name><etal/></person-group><article-title>Interleukin-1 receptor blockade with anakinra provided cessation of fatigue, reduction in inflammation markers and regression of retroperitoneal fibrosis in a patient with Erdheim-Chester disease&#x02014;case study and a review of literature</article-title><source>Vnitr Lek</source><year>2012</year><volume>58</volume><fpage>313</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">22559807</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barlo</surname><given-names>NP</given-names></name><name><surname>van Moorsel</surname><given-names>CH</given-names></name><name><surname>Korthagen</surname><given-names>NM</given-names></name><name><surname>Heron</surname><given-names>M</given-names></name><name><surname>Rijkers</surname><given-names>GT</given-names></name><name><surname>Ruven</surname><given-names>HJ</given-names></name><name><surname>van den Bosch</surname><given-names>JM</given-names></name><name><surname>Grutters</surname><given-names>JC</given-names></name></person-group><article-title>Genetic variability in the IL1RN gene and the balance between interleukin (IL)-1 receptor agonist and IL-1beta in idiopathic pulmonary fibrosis</article-title><source>Clin Exp Immunol</source><year>2011</year><volume>166</volume><fpage>346</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2249.2011.04468.x</pub-id><pub-id pub-id-type="pmid">22059992</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korthagen</surname><given-names>NM</given-names></name><name><surname>van Moorsel</surname><given-names>CH</given-names></name><name><surname>Kazemier</surname><given-names>KM</given-names></name><name><surname>Ruven</surname><given-names>HJ</given-names></name><name><surname>Grutters</surname><given-names>JC</given-names></name></person-group><article-title>IL1RN genetic variations and risk of IPF: a meta-analysis and mRNA expression study</article-title><source>Immunogenetics</source><year>2012</year><volume>64</volume><fpage>371</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1007/s00251-012-0604-6</pub-id><pub-id pub-id-type="pmid">22322675</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aksentijevich</surname><given-names>I</given-names></name><name><surname>Masters</surname><given-names>SL</given-names></name><name><surname>Ferguson</surname><given-names>PJ</given-names></name><name><surname>Dancey</surname><given-names>P</given-names></name><name><surname>Frenkel</surname><given-names>J</given-names></name><name><surname>van Royen-Kerkhoff</surname><given-names>A</given-names></name><name><surname>Laxer</surname><given-names>R</given-names></name><name><surname>Tedgard</surname><given-names>U</given-names></name><name><surname>Cowen</surname><given-names>EW</given-names></name><name><surname>Pham</surname><given-names>TH</given-names></name><etal/></person-group><article-title>An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist</article-title><source>N Eng J Med</source><year>2009</year><volume>360</volume><fpage>2426</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0807865</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berkun</surname><given-names>Y</given-names></name><name><surname>Ben-Chetrit</surname><given-names>E</given-names></name><name><surname>Klar</surname><given-names>A</given-names></name><name><surname>Ben-Chetrit</surname><given-names>E</given-names></name></person-group><article-title>Peritoneal adhesions and intestinal obstructions in patients with familial Mediterranean fever&#x02014;are they more frequent?</article-title><source>Semin Arthritis Rheum</source><year>2007</year><volume>36</volume><fpage>316</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.semarthrit.2006.11.002</pub-id><pub-id pub-id-type="pmid">17240429</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paydas</surname><given-names>S</given-names></name><name><surname>Gokel</surname><given-names>Y</given-names></name></person-group><article-title>Different renal pathologies associated with hypothyroidism</article-title><source>Renal Fail</source><year>2002</year><volume>24</volume><fpage>595</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1081/JDI-120013962</pub-id></element-citation></ref></ref-list></back></article>